@joshua/diabetes-and-endocrine-emergencies

Diabetes and endocrine emergencies

Author-made · not reviewedEndocrinologyCC BY 4.0

Written by the BenchClub team with AI help. Answers follow public guidelines and textbooks; not yet reviewed by a practising physician.

v130 questionsUpdated Nov 18, 2026

Run it
  1. DM-001Multiple choiceEndocrinologyAdvanced

    A 74-year-old man with type 2 diabetes has had thirst, polyuria and poor oral intake for 5 days and is drowsy today. BP 108/64 mm Hg. Labs: glucose 650 mg/dL, sodium 138 mEq/L, BUN 17 mg/dL, venous pH 7.37, bicarbonate 23 mEq/L, β-hydroxybutyrate 0.7 mmol/L. Applying the 2024 ADA/EASD/JBDS/AACE/DTS consensus criteria for hyperglycemic crises, which interpretation is correct?

    1. ADoes not meet HHS criteria: effective osmolality is below 320 mOsm/kg
    2. BMeets criteria for hyperglycemic hyperosmolar state (HHS)
    3. CDoes not meet HHS criteria: the sodium is normal, so he is not hyperosmolar
    4. DDoes not meet HHS criteria: a β-hydroxybutyrate of 0.7 mmol/L excludes HHS
    5. EMeets criteria for combined DKA–HHS
    Show answer

    Answer B

    Source ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024)

  2. DM-002Multiple choiceEndocrinologyAdvanced

    A 26-year-old woman with type 1 diabetes has vomited for 2 days after gastroenteritis. Weight 55 kg, BP 100/64 mm Hg, HR 116/min. Labs: glucose 411 mg/dL, venous pH 7.15, bicarbonate 9 mEq/L, β-hydroxybutyrate 5.1 mmol/L, potassium 3.4 mEq/L, sodium 134 mEq/L; urine output is normal. IV 0.9% saline has been started. Per the 2024 ADA/EASD/JBDS/AACE/DTS consensus, which approach to insulin and potassium is correct?

    1. AStart insulin 0.1 units/kg/h now and add 20–30 mEq KCl to each liter of fluid
    2. BGive an IV insulin bolus of 0.1 units/kg, then 0.14 units/kg/h; replace potassium only if <3.0 mEq/L
    3. CGive IV potassium first and start the insulin infusion once potassium is ≥3.5 mEq/L
    4. DStart a low-dose insulin infusion of 0.05 units/kg/h now with oral potassium
    5. EGive IV sodium bicarbonate first; potassium will rise as acidosis corrects, then start insulin
    Show answer

    Answer C

    Source ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024)

  3. DM-004Multiple choiceEndocrinologyAdvanced

    A 56-year-old man with type 2 diabetes takes dapagliflozin 10 mg daily and metformin. On postoperative day 2 after laparoscopic cholecystectomy he is eating poorly with nausea and vomiting. BP 110/70 mm Hg, HR 108/min. Labs: glucose 173 mg/dL, venous pH 7.19, bicarbonate 12 mEq/L, sodium 136 mEq/L, chloride 101 mEq/L, potassium 4.2 mEq/L, β-hydroxybutyrate 4.9 mmol/L, lactate 1.4 mmol/L, creatinine normal. What is the most appropriate management?

    1. AGlucose is below 200 mg/dL so this is not DKA; stop dapagliflozin, observe and encourage oral intake
    2. BStop dapagliflozin; give IV fluids and an insulin infusion together with dextrose-containing fluids
    3. CTreat as metformin-associated lactic acidosis: stop metformin and arrange hemodialysis
    4. DGive IV sodium bicarbonate and withhold insulin for now to avoid hypoglycemia
    5. EUse subcutaneous rapid-acting insulin by sliding scale and continue dapagliflozin for renal protection
    Show answer

    Answer B

    Source ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024); ADA Standards of Care in Diabetes—2026

  4. DM-005Multiple choiceEndocrinologyAdvanced

    A 58-year-old woman with type 2 diabetes and obesity has taken semaglutide 1 mg subcutaneously once weekly for a year on a stable dose. She has no nausea, vomiting, bloating or other GI symptoms. She is scheduled for elective laparoscopic cholecystectomy under general anesthesia. Per the 2024 ASA/AGA/ASMBS/ISPCOP/SAGES multisociety guidance, what is most appropriate?

    1. AHold semaglutide for 1 week before surgery because delayed gastric emptying raises aspiration risk
    2. BHold semaglutide 3 days before surgery and bridge with basal insulin
    3. CContinue semaglutide because she is on a stable dose without GI symptoms; consider a liquid diet for 24 hours before surgery
    4. DHold semaglutide for 2 weeks and confirm gastric emptying by routine gastric ultrasound before induction
    5. EPostpone surgery until semaglutide has been held for five half-lives (about 5 weeks)
    Show answer

    Answer C

    Source ASA/AGA/ASMBS/ISPCOP/SAGES multisociety clinical practice guidance on GLP-1 receptor agonists in the perioperative period (2024)

  5. DM-006Multiple choiceEndocrinologyAdvanced

    A 52-year-old man with type 1 diabetes and ESKD on hemodialysis three times weekly (anuric) missed a session yesterday and now has nausea and vomiting. BP 162/94 mm Hg, mild leg edema, fine basal crackles. Labs: glucose 739 mg/dL, venous pH 7.21, bicarbonate 13 mEq/L, β-hydroxybutyrate 4.4 mmol/L, potassium 6.2 mEq/L (no hyperkalemic ECG changes), sodium 127 mEq/L. What is the most appropriate management?

    1. AGive 1–1.5 L of 0.9% saline per the standard DKA protocol, then start the insulin infusion
    2. BDialyze urgently to correct acidosis and potassium first, and start insulin after dialysis
    3. CGive IV sodium bicarbonate for the acidosis and subcutaneous rapid-acting insulin
    4. DCorrect the hyponatremia with IV 3% saline first, then start insulin
    5. EAvoid routine large-volume fluids; start IV insulin now, withhold potassium, recheck every 1–2 h and arrange urgent dialysis
    Show answer

    Answer E

    Source ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024); JBDS-IP/Renal Association guidance on diabetes management in adults on haemodialysis (Diabet Med 2018)

  6. DM-007Multiple choiceEndocrinologyIntermediate

    A 58-year-old woman with type 2 diabetes accidentally took ten 5-mg tablets of glyburide (glibenclamide). Despite an IV bolus of 50% dextrose and a continuous 10% dextrose infusion, her glucose repeatedly falls to 45–54 mg/dL. What is the most appropriate next step?

    1. AOctreotide 50 mcg subcutaneously every 6 hours, continuing dextrose
    2. BGlucagon 1 mg IM, repeated every 1–2 hours
    3. CMethylprednisolone 40 mg IV every 12 hours
    4. DHemodialysis to remove glyburide
    5. EStop the dextrose infusion to avoid stimulating insulin release
    Show answer

    Answer A

    Source Goldfrank's Toxicologic Emergencies, 11th ed. (2019); Glatstein M et al. Octreotide for the treatment of sulfonylurea poisoning (Clin Toxicol 2012)

  7. DM-008Multiple choiceEndocrinologyIntermediate

    A 71-year-old man (70 kg) has HHS with moderate dehydration and no shock. Labs: glucose 865 mg/dL, sodium 152 mEq/L, BUN 45 mg/dL, calculated osmolality (2Na + glucose/18 + BUN/2.8) 368 mOsm/kg, β-hydroxybutyrate 0.6 mmol/L, venous pH 7.34. Per the 2022 JBDS-IP HHS guideline, which initial management is most appropriate?

    1. AIV insulin bolus 0.1 units/kg now, then 0.1 units/kg/h, together with fluids
    2. BBecause of hypernatremia, give rapid 0.45% saline and start insulin at the same time
    3. CStart insulin with fluids, aiming for glucose below 180 mg/dL within 6 hours
    4. D0.9% saline alone first; start insulin 0.05 units/kg/h once glucose stops falling with fluids
    5. EGive IV sodium bicarbonate with the fluids to prevent worsening acidosis
    Show answer

    Answer D

    Source JBDS-IP guideline: The management of the hyperosmolar hyperglycaemic state (HHS) in adults (2022 update)

  8. DM-009Multiple choiceEndocrinologyAdvanced

    A 72-year-old woman (60 kg) has HHS (β-hydroxybutyrate 0.8 mmol/L, venous pH 7.35). Following the 2022 JBDS-IP guideline she has received about 2.5 L of 0.9% saline alone over 4 hours. Glucose has fallen from 937 to 613 mg/dL, sodium has risen from 154 to 157 mEq/L, and BUN has fallen from 56 to 50 mg/dL. Urine output is 1.0 mL/kg/h and she is more alert. What is the correct interpretation and plan?

    1. AOsmolality and glucose are falling at appropriate rates; the sodium rise is acceptable, so continue 0.9% saline
    2. BThe sodium rise means too much sodium: switch now to 0.45% saline or 5% dextrose
    3. CGlucose is falling too slowly: start a fixed-rate insulin infusion at 0.05 units/kg/h
    4. DOsmolality is falling too fast with a risk of cerebral edema: slow the fluid rate
    5. ESodium keeps rising: give furosemide to promote natriuresis and slow the fluids
    Show answer

    Answer A

    Source JBDS-IP guideline: The management of the hyperosmolar hyperglycaemic state (HHS) in adults (2022 update)

  9. DM-010Multiple choiceEndocrinologyIntermediate

    According to the 2024 ADA/EASD/JBDS/AACE/DTS consensus on hyperglycemic crises in adults, which statement about DKA management is correct?

    1. AAt a venous pH of 7.08, IV sodium bicarbonate should be given routinely to speed correction
    2. BNegative urine ketones are required for resolution; IV insulin continues until they clear
    3. CPhosphate below the normal range (<2.5 mg/dL) should routinely be replaced IV to prevent weakness
    4. DIV insulin can be stopped and switched to subcutaneous once glucose reaches 250 mg/dL
    5. EDKA can be considered resolved when β-hydroxybutyrate is <0.6 mmol/L and venous pH is ≥7.3
    Show answer

    Answer E

    Source ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024)

  10. DM-012Multiple choiceEndocrinologyBasic

    A 66-year-old man has had type 2 diabetes for 12 years and takes metformin 1000 mg twice daily and glipizide 5 mg daily. His eGFR is now 27 mL/min/1.73 m² (34 three months ago), urine albumin-to-creatinine ratio 420 mg/g, HbA1c 7.3%; no heart failure. He already takes maximally tolerated losartan. What is the most appropriate change?

    1. AReduce metformin to 500 mg twice daily and continue
    2. BKeep the current regimen and adjust only when eGFR falls below 15
    3. CStop metformin and add an SGLT2 inhibitor
    4. DStop metformin and switch glipizide to glyburide
    5. EStop all oral agents and start a four-injection daily insulin regimen
    Show answer

    Answer C

    Source KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD; ADA Standards of Care in Diabetes—2026, Sections 9 and 11

  11. DM-013Multiple choiceEndocrinologyBasic

    A 29-year-old primigravida with normal glucose before pregnancy has a one-step 75-g OGTT at 25 weeks: fasting 86 mg/dL, 1-hour 184 mg/dL, 2-hour 150 mg/dL. Using the one-step strategy in the ADA Standards of Care, what is the correct interpretation?

    1. ANot diagnostic: two or more values must meet or exceed the thresholds
    2. BGestational diabetes: the 1-hour value alone meets the diagnostic threshold
    3. CNot diagnostic: the fasting value is below 92 mg/dL
    4. DImpaired glucose tolerance only; repeat an OGTT 4–12 weeks postpartum
    5. EOvert (pregestational) diabetes requiring insulin
    Show answer

    Answer B

    Source ADA Standards of Care in Diabetes—2026, Section 2 (one-step 75-g OGTT, IADPSG thresholds)

  12. DM-014Multiple choiceEndocrinologyIntermediate

    A 36-year-old woman with Graves disease stopped her medication 6 months ago. On postoperative day 1 after appendectomy she develops fever 40.1 °C (104.2 °F), agitation and delirium, atrial fibrillation at 162/min, diaphoresis and diarrhea; free T4 is markedly elevated and the Burch-Wartofsky score is 105. BP 118/70 mm Hg, no heart failure, no asthma; a nasogastric tube is in place. Per the 2016 ATA guideline, which regimen is most appropriate?

    1. AIodine (SSKI or Lugol's) + propranolol + hydrocortisone, with propylthiouracil 1 hour later
    2. BMethimazole + propranolol + hydrocortisone + aspirin for fever
    3. CAmiodarone cardioversion + methimazole + iodine + cooling blankets
    4. DPropranolol + hydrocortisone to stabilize, then radioactive iodine as soon as possible
    5. EPropranolol + propylthiouracil, then iodine (SSKI or Lugol's) at least 1 hour later + hydrocortisone + acetaminophen
    Show answer

    Answer E

    Source 2016 ATA Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

  13. DM-015Multiple choiceEndocrinologyBasic

    A 47-year-old woman with primary adrenal insufficiency on hydrocortisone 15 mg/day and fludrocortisone has vomited for 2 days with gastroenteritis and cannot keep medication down. BP 76/44 mm Hg, HR 124/min, sodium 127 mEq/L, potassium 5.7 mEq/L, glucose 63 mg/dL. What is the most appropriate management?

    1. ADraw cortisol and ACTH and decide the steroid dose when results return; give fluids meanwhile
    2. BHydrocortisone 100 mg IV now, rapid 0.9% saline infusion, and correction of hypoglycemia
    3. CDouble oral hydrocortisone to 30 mg/day, give an antiemetic and observe with fluids
    4. DHydrocortisone 25 mg IV with a rapid infusion of 5% dextrose in water
    5. ESupport BP with norepinephrine and give steroids after a cosyntropin stimulation test
    Show answer

    Answer B

    Source Endocrine Society Clinical Practice Guideline: Diagnosis and Treatment of Primary Adrenal Insufficiency (2016)

  14. DM-016Multiple choiceEndocrinologyIntermediate

    A 42-year-old woman has had 6 months of paroxysmal headache, palpitations and sweating, with BP up to 220/120 mm Hg during episodes. Plasma free metanephrines are about 6 times the upper limit, and CT shows a 4.5-cm left adrenal mass. Laparoscopic adrenalectomy is planned. Which preoperative preparation is correct?

    1. Aα-blockade (e.g., phenoxybenzamine or doxazosin) for 7–14 days with a high-sodium diet and fluids; a β-blocker only after α-blockade if tachycardic
    2. BStart metoprolol to control heart rate, then add an α-blocker after 1 week
    3. CControl BP with hydrochlorothiazide plus enalapril and operate promptly
    4. DNo preoperative medication; operate promptly and control BP with intraoperative nitroprusside
    5. EOnce α-blockade takes effect, restrict salt and fluids to prevent rebound hypertension
    Show answer

    Answer A

    Source Endocrine Society Clinical Practice Guideline: Pheochromocytoma and Paraganglioma (2014)

  15. DM-017Multiple choiceEndocrinologyIntermediate

    A 64-year-old man with squamous cell lung cancer has had a week of fatigue, polyuria and confusion and is clinically very dry; no history of heart failure. Albumin-corrected calcium 15.6 mg/dL, PTH suppressed, creatinine 1.5 mg/dL. What is the most appropriate initial management?

    1. AFurosemide 40 mg IV now to promote calciuria, with fluid restriction
    2. BIV 0.9% saline + calcitonin + IV zoledronic acid or denosumab
    3. CIV phosphate to bind calcium and lower it quickly
    4. DZoledronic acid 4 mg alone, restricting fluids to avoid cardiac overload
    5. EHemodialysis as first-line therapy, with IV methylprednisolone to suppress bone resorption
    Show answer

    Answer B

    Source Endocrine Society Clinical Practice Guideline: Treatment of Hypercalcemia of Malignancy in Adults (2023)

  16. DM-018Multiple choiceEndocrinologyBasic

    A 70-year-old man with small cell lung cancer has had 2 days of headache and vomiting and had a generalized tonic-clonic seizure 1 hour ago; he is now somnolent. Sodium 113 mEq/L, serum osmolality 238 mOsm/kg, urine osmolality 520 mOsm/kg, urine sodium 58 mEq/L; clinically euvolemic. What is the most appropriate emergency treatment?

    1. A3% saline bolus (100–150 mL over 10–20 min), repeated up to 2–3 times until symptoms improve or sodium rises 4–6 mEq/L
    2. BFluid restriction to 800 mL/day with sodium checks every 6 hours
    3. COral tolvaptan 15 mg and recheck sodium the next day
    4. DRapid infusion of 2 L of 0.9% saline to correct the hypotonic state
    5. EContinuous 3% saline aiming for sodium of 130 mEq/L within 24 hours
    Show answer

    Answer A

    Source Verbalis JG et al. Hyponatremia treatment guidelines 2013: expert panel recommendations (Am J Med 2013); ESE/ESICM/ERBP Clinical practice guideline on hyponatraemia (2014)

  17. DM-019Multiple choiceEndocrinologyAdvanced

    A 55-year-old man with chronic alcohol use and malnutrition is admitted with weakness. Sodium 106 mEq/L, potassium 3.0 mEq/L, no seizures. After 0.9% saline and potassium replacement he develops a large dilute diuresis (>300 mL/h), and 10 hours later sodium is 117 mEq/L; he is alert. What is the most appropriate next step?

    1. AThe 11 mEq/L rise in 10 hours is within the 12 mEq/L 24-hour limit, so continue the current plan
    2. BSwitch to 3% saline to maintain the current rate of correction
    3. CGive furosemide 20 mg IV to reduce water retention
    4. DStop sodium-containing fluids, give 5% dextrose in water and consider desmopressin to relower the sodium
    5. EAdd tolvaptan 7.5 mg to speed further correction
    Show answer

    Answer D

    Source Verbalis JG et al. Hyponatremia treatment guidelines 2013: expert panel recommendations (Am J Med 2013); ESE/ESICM/ERBP Clinical practice guideline on hyponatraemia (2014)

  18. DM-020Multiple choiceEndocrinologyIntermediate

    A 79-year-old woman who had a total thyroidectomy stopped levothyroxine on her own a year ago. In winter she is found poorly responsive. Temperature 33.8 °C (92.8 °F), HR 46/min, BP 92/58 mm Hg, GCS 9, generalized nonpitting edema. Sodium 123 mEq/L, glucose 70 mg/dL, PaCO₂ 64 mm Hg, TSH 86 mU/L, free T4 markedly low. Besides intubation and supportive care, which management is most appropriate?

    1. AIV hydrocortisone 100 mg every 8 hours plus an IV levothyroxine loading dose of about 200 mcg, then daily IV maintenance
    2. BOral levothyroxine 25 mcg/day, increasing by 25 mcg every 2 weeks to avoid myocardial ischemia
    3. CIV levothyroxine 300 mcg load, deciding on steroids after the cortisol result returns
    4. DIV liothyronine (T3) 100 mcg every 8 hours for rapid correction
    5. EActive external rewarming with heating blankets first, then thyroid hormone once normothermic
    Show answer

    Answer A

    Source ATA Guidelines for the Treatment of Hypothyroidism (2014)

  19. DM-021Multiple choiceEndocrinologyBasic

    A 51-year-old man with a known, untreated pituitary macroadenoma has sudden severe headache and vomiting, worsening bitemporal field loss and a new right ptosis. BP 88/54 mm Hg, sodium 129 mEq/L; MRI shows hemorrhage into the tumor. What is the most urgent drug treatment?

    1. AOral levothyroxine 100 mcg to correct secondary hypothyroidism
    2. BOral bromocriptine 2.5 mg to shrink the tumor
    3. CDraw a cortisol level, then give hydrocortisone 100 mg IV immediately
    4. D20% mannitol 125 mL IV to lower intracranial pressure, then observe vision
    5. EIV heparin to prevent cavernous sinus thrombosis
    Show answer

    Answer C

    Source Rajasekaran S et al. UK guidelines for the management of pituitary apoplexy (Clin Endocrinol 2011)

  20. DM-022Multiple choiceEndocrinologyIntermediate

    A 24-year-old man wakes unable to stand after a large late-night meal of rice and sweets. He is alert with no dyspnea. HR 118/min, BP 132/70 mm Hg, no history of asthma or heart failure; leg strength 2/5, reduced reflexes. Potassium 1.9 mEq/L, TSH <0.01 mU/L, free T4 markedly elevated; ECG shows U waves. Apart from antithyroid therapy, what is the most appropriate acute management?

    1. AHigh-dose IV potassium at 40 mEq/h until the level is normal
    2. BIV dextrose with insulin to shift potassium into cells
    3. COral spironolactone to conserve potassium, without replacement
    4. DSelective β1-blocker metoprolol plus acetazolamide to prevent attacks
    5. ELow-dose IV KCl (≤10 mEq/h, limited total dose) plus nonselective propranolol, with ECG monitoring and serial potassium checks for rebound hyperkalemia
    Show answer

    Answer E

    Source Lin SH. Thyrotoxic periodic paralysis (Mayo Clin Proc 2005); Kung AW. Thyrotoxic periodic paralysis: a diagnostic challenge (J Clin Endocrinol Metab 2006); 2016 ATA hyperthyroidism guideline (antithyroid and definitive therapy)

  21. DM-031Multiple choiceEndocrinologyAdvanced

    A 31-year-old woman with type 1 diabetes has had 4 days of nausea and repeated vomiting and has taken little insulin. Labs: glucose 450 mg/dL, sodium 134 mEq/L, chloride 86 mEq/L, bicarbonate 16 mEq/L, potassium 3.8 mEq/L, BUN 32 mg/dL, creatinine 1.4 mg/dL, albumin 4.2 g/dL, β-hydroxybutyrate 9.0 mmol/L, lactate 1.4 mmol/L; measured serum osmolality 309 mOsm/kg (calculated 304); arterial pH 7.34, PaCO₂ 31 mm Hg. Which best describes her acid–base status?

    1. AAnion-gap metabolic acidosis alone, with appropriate respiratory compensation
    2. BAnion-gap metabolic acidosis with a concurrent normal-anion-gap (hyperchloremic) metabolic acidosis
    3. CAnion-gap metabolic acidosis with a concurrent primary respiratory alkalosis
    4. DAnion-gap metabolic acidosis with a concurrent metabolic alkalosis; respiratory compensation is appropriate
    5. EAnion-gap metabolic acidosis with a concurrent primary respiratory acidosis
    Show answer

    Answer D

    Source Berend K, de Vries APJ, Gans ROB. Physiological approach to assessment of acid–base disturbances (N Engl J Med 2014); ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024)

  22. DM-032Multiple choiceEndocrinologyIntermediate

    A 67-year-old man with an ICD has taken amiodarone 200 mg daily for 3 years for recurrent ventricular tachycardia; he has no history of thyroid disease. He has 3 weeks of palpitations, tremor and weight loss. TSH <0.01 mU/L, free T4 3.6 ng/dL (reference 0.8–1.8), free T3 elevated, TSH-receptor antibodies negative. The thyroid is not enlarged and has no nodules; color-flow Doppler shows absent vascularity, and 24-hour radioactive iodine uptake is 1%. Cardiology advises that amiodarone must continue. What is the most appropriate treatment?

    1. ARadioactive iodine ablation
    2. BMethimazole 40 mg daily as monotherapy
    3. CPropylthiouracil plus SSKI (potassium iodide)
    4. DPrednisone about 40 mg daily, tapered over roughly 3 months
    5. ENo specific therapy; thyrotoxicosis will settle while amiodarone continues
    Show answer

    Answer D

    Source 2016 ATA Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (amiodarone-induced thyrotoxicosis); Bartalena L et al. 2018 ETA Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction (Eur Thyroid J 2018)

  23. DM-023Short answerEndocrinologyAdvanced

    A 19-year-old woman (60 kg) with newly diagnosed type 1 diabetes has 2 weeks of polydipsia and polyuria and 1 day of vomiting. BP 96/58 mm Hg, HR 122/min, deep rapid breathing. Labs: glucose 510 mg/dL, venous pH 7.06, bicarbonate 6 mEq/L, β-hydroxybutyrate 6.4 mmol/L, sodium 130 mEq/L, potassium 5.9 mEq/L, creatinine 1.3 mg/dL. Write the plan for the first 4 hours: fluids, insulin (give the rate), potassium, whether to give bicarbonate, monitoring, and the key adjustments that follow.

    Rubric

    • +2Isotonic crystalloid about 500–1000 mL/h for the first 2–4 h (15–20 mL/kg, about 0.9–1.2 L, in the first hour also accepted)
    • +2Insulin 0.1 units/kg/h by continuous IV infusion, about 6 units/h
    • +2Potassium >5.0 mEq/L (JBDS >5.5): withhold and recheck in 2 h; once below the threshold with urine output, add 20–40 mEq KCl per liter (or 10–20 mEq/h)
    • +1States pH ≥7.0 so no bicarbonate
    • +2Adds dextrose when glucose falls below 250 mg/dL and continues insulin until resolution (β-hydroxybutyrate <0.6 mmol/L and pH ≥7.3 or bicarbonate ≥18 mEq/L)
    • +1Hourly glucose; electrolytes, blood gas and β-hydroxybutyrate every 2–4 h
    • +1Calculates corrected sodium (about 137–140 mEq/L) and uses it with the clinical picture to choose subsequent fluid
    • -3Gives bicarbonate, gives potassium while it is 5.9 mEq/L, or stops IV insulin when glucose falls
    Show answer

    Reference answer Fluids: 0.9% saline or a balanced crystalloid, about 1 L in the first hour given her hypotension (15–20 mL/kg; the 2024 consensus gives 500–1000 mL/h for the first 2–4 hours), then adjusted to hemodynamics and urine output (roughly 250–500 mL/h). Corrected sodium is about 137–140 mEq/L (130 + 1.6–2.4 per 100 mg/dL of glucose above 100), which guides later choice of 0.9% vs 0.45% saline. Insulin: fixed-rate 0.1 units/kg/h IV, i.e., 6 units/h; a bolus is optional. Potassium: 5.9 is above 5.0 mEq/L (JBDS uses 5.5), so withhold potassium and recheck in 2 hours; once below the threshold and urine output is adequate, add 20–40 mEq KCl per liter (about 10–20 mEq/h) to keep potassium 4–5 mEq/L. pH 7.06 is ≥7.0, so no bicarbonate. Monitoring: hourly glucose, electrolytes, venous gas and β-hydroxybutyrate every 2–4 hours, strict intake/output. When glucose falls below 250 mg/dL, add 5–10% dextrose and continue insulin (may reduce to 0.05 units/kg/h) until DKA resolves: β-hydroxybutyrate <0.6 mmol/L and venous pH ≥7.3 or bicarbonate ≥18 mEq/L. Starting a low dose of SC basal insulin (e.g., 0.15–0.3 units/kg) early while the infusion continues is acceptable per the consensus. In a young patient watch for cerebral edema and avoid overly rapid falls in glucose and osmolality. Look for the precipitant.

    Source ADA/EASD/JBDS/AACE/DTS consensus report: Hyperglycemic Crises in Adults With Diabetes (Diabetes Care 2024)

  24. DM-024Short answerEndocrinologyIntermediate

    An 81-year-old woman with type 2 diabetes uses insulin glargine 16 units/day and glimepiride 4 mg/day. She lives alone and has had a poor appetite recently. HbA1c 6.2%, eGFR 38 mL/min/1.73 m². Family find her unresponsive in the morning; fingerstick glucose is 34 mg/dL. Write: immediate emergency treatment, management and observation after she wakes, and the regimen change before discharge.

    Rubric

    • +1Immediate IV dextrose 25 g (D50 50 mL or D10 equivalent)
    • +1Glucagon 1 mg IM/SC, 3 mg intranasal or dasiglucagon 0.6 mg SC if no IV access
    • +1Recognizes hypoglycemia will recur (long-acting sulfonylurea with reduced eGFR)
    • +1Admits for at least 24 h with glucose checks every 1–2 h (dextrose infusion and/or octreotide acceptable)
    • +2Stops glimepiride
    • +2States an explicit relaxed or individualized HbA1c goal (e.g., <8.0%), separate from stopping glimepiride
    • +2Reduces the basal insulin dose and provides family education plus a glucagon prescription or CGM
    • -3Discharges her as soon as she wakes, without observation
    Show answer

    Reference answer Immediately: IV access and 25 g dextrose IV (50 mL of D50, or 250 mL of D10); without IV access give glucagon 1 mg IM/SC, 3 mg intranasal or dasiglucagon 0.6 mg SC (may be less effective with poor intake), then recheck in 15 minutes. Do not give oral glucose while she is unresponsive. Once awake, give food with complex carbohydrate. Glimepiride is long-acting and her renal function is reduced, so hypoglycemia is likely to recur: run a continuous 10% dextrose infusion and admit, with glucose checks every 1–2 hours until she is stable off dextrose (typically at least 24 hours, longer with a long-acting sulfonylurea and eGFR 38). For hypoglycemia that recurs despite dextrose, consider octreotide. Before discharge: stop glimepiride; reduce glargine (e.g., by 20%); after a level 3 event in an older adult living alone, relax the HbA1c target to <8.0%; teach family to recognize hypoglycemia, prescribe glucagon, and consider CGM.

    Source ADA Standards of Care in Diabetes—2026, Sections 6 and 13

  25. DM-025Short answerEndocrinologyAdvanced

    A 27-year-old woman with Graves disease is in week 6 of methimazole 30 mg/day. She has had fever 39.2 °C (102.6 °F) and sore throat for 2 days. Absolute neutrophil count 200/μL; hemoglobin and platelets are normal. Free T4 is still 1.5 times the upper limit and HR is 110/min. Outline the management, including the subsequent treatment of her hyperthyroidism.

    Rubric

    • +3Stops methimazole now and permanently avoids all thionamides, including propylthiouracil
    • +2Treats as febrile neutropenia: blood cultures then immediate empiric antipseudomonal broad-spectrum therapy
    • +1Considers G-CSF
    • +1β-blocker for rate control
    • +1Names at least one appropriate non-thionamide bridge (cholestyramine, glucocorticoids if storm, lithium, iodine before surgery) and notes that iodine delays radioactive iodine
    • +1Recognizes and assesses for infection-triggered thyroid storm (e.g., Burch-Wartofsky)
    • +2Definitive therapy with radioactive iodine (exclude pregnancy, assess eye disease) or thyroidectomy after neutrophil recovery
    • -3Switches to propylthiouracil to continue antithyroid drug therapy
    Show answer

    Reference answer Stop methimazole immediately and never use any thionamide again; do not switch to propylthiouracil (cross-reactivity). Manage as febrile neutropenia: neutropenic precautions, blood cultures, then immediate empiric broad-spectrum antipseudomonal β-lactam (e.g., cefepime or piperacillin-tazobactam). G-CSF may be considered. Infection can precipitate thyroid storm, so assess (Burch-Wartofsky) and monitor closely. Control heart rate with a β-blocker; bridge the thyrotoxicosis with cholestyramine and/or glucocorticoids (use steroids cautiously during active infection; they are indicated if thyroid storm is suspected), with lithium as an adjunct; reserve inorganic iodine mainly for preoperative preparation because it impairs later radioactive iodine uptake. Once neutrophils recover, give definitive therapy: radioactive iodine (exclude pregnancy and breastfeeding, assess Graves orbitopathy and consider steroid prophylaxis, avoid pregnancy for at least 6 months) or thyroidectomy (preferred with a large goiter, moderate-to-severe active orbitopathy, or a wish for rapid definitive control or near-term pregnancy; prepare with iodine etc. to bring her as close to euthyroid as possible). Document the thionamide contraindication in the record.

    Source 2016 ATA Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

  26. DM-026Short answerEndocrinologyIntermediate

    A 63-year-old man with type 2 diabetes is admitted to the ICU after CABG, mechanically ventilated and NPO. Two glucose readings 6 hours after surgery are 249 and 263 mg/dL. At home he took metformin and sitagliptin. Write: the glucose target, the insulin regimen, what to do with the oral agents, and what to avoid.

    Rubric

    • +3Target 140–180 mg/dL for most critically ill patients (full credit also for a stricter 110–140 mg/dL goal in selected patients such as after cardiac surgery, if stated as achievable without significant hypoglycemia; +1 only if a stricter goal is given without that caveat)
    • +2Continuous IV insulin infusion, adjusted by protocol with checks every 30 min–2 h
    • +1Stops metformin and sitagliptin
    • +2States that a target of about 80–110 mg/dL should not be pursued (more hypoglycemia and death)
    • +1Provides dextrose or nutrition while NPO and a hypoglycemia protocol
    • +1Switches to basal–prandial–correction SC insulin once eating (basal about 60–80% of the infusion-derived daily dose), giving basal 2–4 h before stopping the infusion
    • -2Uses subcutaneous sliding-scale insulin alone
    • -1Schedules prandial SC insulin while he is NPO and intubated
    Show answer

    Reference answer Target 140–180 mg/dL for critically ill patients; a lower target of 110–140 mg/dL may be acceptable for selected patients (e.g., after cardiac surgery, per institutional and surgical-society practice) if it can be reached without significant hypoglycemia. Start a continuous IV insulin infusion once glucose is persistently ≥180 mg/dL, adjusted by protocol with glucose checks every 30 minutes to 2 hours. Stop metformin and sitagliptin. Do not pursue intensive control at 80–110 mg/dL (NICE-SUGAR: more severe hypoglycemia and higher mortality). Do not use subcutaneous sliding-scale insulin alone. Provide glucose or nutrition while NPO and have a hypoglycemia protocol. After extubation and resumption of eating, switch to a subcutaneous basal–prandial–correction regimen, giving basal insulin 2–4 hours before stopping the infusion; the SC basal dose is about 60–80% of the stable infusion-derived daily requirement.

    Source ADA Standards of Care in Diabetes—2026, Section 16 (Diabetes Care in the Hospital)

  27. DM-027Short answerEndocrinologyIntermediate

    A 68-year-old man with type 2 diabetes takes metformin 1000 mg twice daily (HbA1c 7.0%, weight 80 kg, normal renal function). He is admitted with a COPD exacerbation and started on prednisone 40 mg every morning for 5 days. Since then fasting glucose is 122–135 mg/dL, but from lunch to bedtime it is 252–324 mg/dL. Explain the glucose pattern, propose an insulin regimen (show the starting-dose calculation) and describe the adjustment when the steroid stops.

    Rubric

    • +2Identifies afternoon-to-bedtime hyperglycemia with near-normal fasting values from morning prednisone
    • +3Chooses morning NPH given together with the prednisone
    • +2Calculates 0.1 units/kg per 10 mg prednisone ≈ 0.4 units/kg ≈ 32 units as the maximum (a start of about 24 units, ≈0.3 units/kg, also accepted)
    • +1Titrates daily by afternoon and bedtime glucose; may add correctional rapid-acting insulin
    • +2Stops NPH the day after the last prednisone dose (or reduces it in proportion if tapered) to prevent hypoglycemia
    • -2Only adds or increases bedtime long-acting basal insulin to control afternoon glucose
    Show answer

    Reference answer Prednisone is intermediate-acting; given once in the morning its peak effect is from early afternoon to evening, causing afternoon and evening hyperglycemia with near-normal fasting values. Regimen: NPH insulin given each morning together with the prednisone, estimated at 0.1 units/kg per 10 mg of prednisone, so 40 mg ≈ 0.4 units/kg × 80 kg ≈ 32 units as the maximum; in this 68-year-old insulin-naive man a start of about 24 units (≈0.3 units/kg) is reasonable. Correctional rapid-acting insulin with meals may be added. Aim for 140–180 mg/dL: raise NPH by 10–20% if afternoon or bedtime glucose stays >180 mg/dL and lower it if any value is <100 mg/dL. Metformin can continue if he is stable, not hypoxic or acidotic, eating normally and with normal renal function; otherwise hold it during admission. Give NPH through the last (day 5) prednisone dose, stop it the next day and keep monitoring for hypoglycemia; if a taper is prescribed instead, reduce NPH in proportion to the prednisone dose.

    Source ADA Standards of Care in Diabetes—2026, Section 16 (Diabetes Care in the Hospital)

  28. DM-028Short answerEndocrinologyIntermediate

    A 58-year-old woman with rheumatoid arthritis has taken prednisone 15 mg/day for 2 years. She is scheduled for open resection of colon cancer and is expected to be NPO for 2–3 days afterwards. Write the perioperative glucocorticoid plan (drugs and doses), the postoperative transition, and what to consider if she develops unexplained hypotension during surgery.

    Rubric

    • +2States prednisone-equivalent ≥5 mg/day for ≥4 weeks risks HPA suppression and needs stress dosing
    • +1Gives the usual prednisone dose (or IV equivalent) on the day of surgery
    • +3Hydrocortisone 100 mg IV at induction
    • +2Then about 150–200 mg hydrocortisone per 24 h until oral intake resumes (200 mg/24 h infusion or 50 mg IV every 6–8 h accepted)
    • +2Once eating, doubles the usual oral dose for 48 h (up to 1 week if complicated) or tapers rapidly, then returns to the usual 15 mg/day
    • +2Unexplained intraoperative hypotension (after excluding bleeding, anesthetic depth, sepsis): considers adrenal insufficiency and gives an extra hydrocortisone 100 mg IV bolus plus IV fluids
    • +1Monitors glucose and electrolytes perioperatively
    • -2Stops prednisone before or on the day of surgery with no replacement or stress dose
    Show answer

    Reference answer Prednisone-equivalent ≥5 mg/day for ≥4 weeks risks HPA-axis suppression, so stress dosing is needed. Give the usual 15 mg prednisone on the morning of surgery (if she cannot take it orally, the induction hydrocortisone covers it). In addition: hydrocortisone 100 mg IV at induction, then 200 mg/24 h by continuous IV infusion (or 50 mg IV/IM every 6 hours) until oral intake resumes. Once eating, double the usual oral dose for 48 hours (up to 1 week if the course is complicated), then return to the usual dose. Intraoperative hypotension not explained by blood loss, anesthetic depth or sepsis should prompt consideration of adrenal insufficiency: give an extra hydrocortisone 100 mg IV and fluids. Monitor glucose and electrolytes perioperatively.

    Source Woodcock T et al. Guidelines for the management of glucocorticoids during the peri-operative period (Association of Anaesthetists/RCP/Society for Endocrinology, 2020); ESE/Endocrine Society guideline on glucocorticoid-induced adrenal insufficiency (2024)

  29. DM-029Short answerEndocrinologyIntermediate

    A 73-year-old woman presents with fatigue and unsteady gait; no headache, vomiting or altered mental status; symptoms have developed over several weeks. She started sertraline 2 months ago. Sodium 124 mEq/L, potassium 4.0 mEq/L, serum osmolality 256 mOsm/kg, urine osmolality 410 mOsm/kg, urine sodium 48 mEq/L; clinically euvolemic; glucose, lipids and protein normal. Write: what else must be excluded before diagnosing SIADH, the treatment plan, and the limits on correction rate.

    Rubric

    • +2Excludes hypothyroidism (TSH) and adrenal insufficiency (cortisol)
    • +1Any 2 of: confirms no diuretic use, assesses renal function, considers pulmonary, CNS or malignant causes
    • +2Identifies sertraline as a likely cause and discusses stopping or switching it
    • +2Fluid restriction first line (<800–1000 mL/day or about 500 mL/day below urine output); if ineffective, oral urea or low-dose loop diuretic with oral salt (tolvaptan with appropriate caveats also accepted)
    • +2States a correction limit consistent with either guideline (ESE ≤10 then ≤8 mEq/L per 24 h, or US ≤10–12 mEq/L per 24 h and ≤18 mEq/L per 48 h)
    • +1Monitors sodium and relowers with 5% dextrose or desmopressin if overcorrected
    • -3Gives a 3% saline bolus or targets correction faster than 12 mEq/L per 24 h despite mild chronic symptoms
    Show answer

    Reference answer Hypotonic hyponatremia with urine osmolality >100 mOsm/kg, urine sodium >30 mEq/L and clinical euvolemia fits SIADH; before confirming it, exclude hypothyroidism (TSH), adrenal insufficiency (morning cortisol), recent diuretic use and renal insufficiency, and look for pulmonary, CNS and malignant causes. Sertraline (an SSRI) is a common cause: discuss stopping or switching it with psychiatry. Symptoms are mild, so no 3% saline. First line is fluid restriction (<800–1000 mL/day); if ineffective, oral urea (0.25–0.50 g/kg/day) or a low-dose loop diuretic with oral sodium chloride; tolvaptan is an option in the US panel recommendations (start in hospital, avoid in liver disease, ≤30 days), but the European guideline advises against vaptans. Correction limits: ESE 2014, ≤10 mEq/L in the first 24 h and ≤8 mEq/L in each subsequent 24 h; US panel 2013, ≤10–12 mEq/L per 24 h and ≤18 mEq/L per 48 h, or ≤8 mEq/L per 24 h if at high risk of osmotic demyelination (sodium ≤105, hypokalemia, alcohol use disorder, malnutrition, liver disease). Recheck sodium regularly and relower with 5% dextrose or desmopressin if overcorrected. Even mild chronic hyponatremia increases falls and fractures, so it should be corrected.

    Source Verbalis JG et al. Hyponatremia treatment guidelines 2013: expert panel recommendations (Am J Med 2013); ESE/ESICM/ERBP Clinical practice guideline on hyponatraemia (2014)

  30. DM-030Short answerEndocrinologyAdvanced

    A 61-year-old man with melanoma is on cycle 5 of pembrolizumab. He has no history of diabetes; fasting glucose 3 months ago was 97 mg/dL. He has had 3 days of polydipsia, polyuria and nausea. Labs: glucose 562 mg/dL, venous pH 7.18, bicarbonate 11 mEq/L, β-hydroxybutyrate 4.6 mmol/L, HbA1c 7.2%, C-peptide <0.1 ng/mL. Write: the diagnosis, acute management, long-term management, and whether to continue immunotherapy.

    Rubric

    • +2Diagnoses immune checkpoint inhibitor–associated diabetes with DKA and recognizes abrupt-onset β-cell failure (HbA1c not commensurate with the hyperglycemia and/or undetectable C-peptide)
    • +1Standard DKA treatment: isotonic fluids and insulin (IV infusion; an SC rapid-acting protocol is acceptable for mild–moderate DKA), then SC basal–bolus with overlap
    • +1Checks potassium before insulin (holds insulin if <3.5 mEq/L) and replaces potassium
    • +2Long-term (usually lifelong) insulin therapy
    • +2States glucocorticoids do not reverse β-cell loss and are not used to treat this diabetes
    • +1Screens for other endocrine irAEs (thyroid function, morning cortisol/ACTH)
    • +2Holds pembrolizumab during the acute event and states it can usually be resumed once DKA resolves and glucose is controlled on insulin (no mandatory permanent discontinuation)
    • -3Treats the diabetes with high-dose glucocorticoids (replacement or stress dosing for coexisting adrenal insufficiency is not penalized)
    Show answer

    Reference answer Diagnosis: immune checkpoint inhibitor–associated diabetes (acute β-cell destruction, resembling fulminant type 1 diabetes) presenting with DKA; the modest HbA1c despite very high glucose and the very low C-peptide indicate abrupt onset. Acute care follows standard DKA treatment: start isotonic fluids immediately, check potassium before insulin (hold insulin if <3.5 mEq/L), then IV insulin and potassium replacement, with overlap to subcutaneous insulin once ketoacidosis resolves. Long term he needs basal–bolus insulin, usually lifelong, with education and endocrinology follow-up. Glucocorticoids do not reverse β-cell loss and are not used to treat this (they worsen hyperglycemia), although replacement or stress-dose hydrocortisone is needed if adrenal insufficiency coexists. Screen for other endocrine irAEs: thyroid function, morning cortisol and ACTH (hypophysitis, adrenalitis); lipase and islet autoantibodies may be checked. This is a grade 3–4 event: hold pembrolizumab. ICI-associated diabetes alone does not mandate permanent discontinuation; pembrolizumab can usually be resumed with oncology once DKA has resolved and glucose is controlled on insulin.

    Source Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)

Report